Ignite Creation Date:
2024-05-05 @ 5:12 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00405171
Status:
COMPLETED
Last Update Posted:
2010-10-28
First Post:
2006-11-27
Brief Title:
Efavirenz to Nevirapine Switch and Low-Density Lipoprotein LDL-Dyslipidemia
Sponsor:
University Hospital Caen
Organization:
University Hospital Caen
Study Overview
Official Title:
Efavirenz to Nevirapine Switch in HIV-1 Infected Patients With Severe Dyslipidemia A Randomized Controlled Study
Status:
COMPLETED
Status Verified Date:
2010-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Dyslipidemia and coronary heart disease CHD are increasingly recognized in persons with human immunodeficiency virus HIV infection Many antiretrovirals including efavirenz EFV are associated with increases in serum lipids The investigators investigated whether stopping EFV and replace EFV by nevirapine can reduce significantly Low-Density Lipoprotein cholesterol while keeping virologic control of HIV
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None